Abivax SA American Share... (ABVX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
6.35
0.20 (3.25%)
At close: Jan 15, 2025, 1:00 PM
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Abivax SA American Shares
Country | United States |
IPO Date | Oct 20, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 62 |
CEO | Marc M. P. de Garidel M.B.A. |
Contact Details
Address: 7-11 boulevard Haussmann Paris, United States | |
Website | https://www.abivax.com |
Stock Details
Ticker Symbol | ABVX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001956827 |
CUSIP Number | n/a |
ISIN Number | US00370M1036 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Marc M. P. de Garidel M.B.A. | Chief Executive Officer & Director |
Didier Blondel | EVice President, Chief Financial Officer & Board Secretary |
Ana Sharma M.P.H. | Vice President & Global Head of Quality |
Chris Rabbat Ph.D. | Vice President & Global Head of Medical Affairs |
Didier Scherrer Ph.D. | Chief Scientific Officer |
Hema Keshava | Senior Vice President of Finance |
Ida Hatoum | Chief People & Compliance Officer |
Jerome Denis Ph.D. | Executive Vice President of Process Development & Manufacturing |
Patrick Malloy | Senior Vice President of Investor Relations |
Pierre Courteille M.B.A. | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 10, 2025 | 6-K | Filing |
Dec 23, 2024 | 6-K | Filing |
Nov 19, 2024 | 6-K | Filing |
Nov 19, 2024 | F-3 | Filing |
Nov 14, 2024 | 6-K | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 03, 2024 | 6-K | Filing |
Oct 03, 2024 | 6-K | Filing |
Sep 26, 2024 | 6-K | Filing |
Sep 25, 2024 | 6-K | Filing |